Ustekinumab in clinical practice: Response depends on dose and previous treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 4, 2012, Pages 508-513

  Ruiz Salas, V ^a   Puig, L ^a   Alomar, A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

USTEKINUMAB;

ADULT; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PARONYCHIA; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; REVIEW; TOOTH INFECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84858866631     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04325.x     Document Type: Review

References (13)

1. Stelara summay of product characteristics. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000958/WC500058513.pdf (last accessed: 13 June 2010).
2. Farhi D,. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. Drugs Today (Barc) 2010; 46: 259-264.
3. Puig L, Carrascosa JM, Daudén E, et al. Spanish evidence-based guidelines on the treatment of moderate to severe psoriasis with biologics agents. Actas Dermosifiliogr 2009; 100: 386-413.
4. Fredriksson T, Pettersson U,. Severe psoriasis-Oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
5. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
6. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
7. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-579.
8. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
9. Griffiths CEM,. Comparing biological therapies in psoriasis: implications for clinical practice. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 6): 10-14.
10. Clemmensen A, Spon M, Skov L, Zacharie C, Gniadecki R,. Responses to ustekinumab in the anti-TNF agent-naá®ve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1040.
11. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2010; 70: 284-288.
12. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275. (Pubitemid 47048857)
13. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275. (Pubitemid 47048857)